Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells

Abstract

Li Jiaxuan, Feng Yinglu. Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells[J]. Journal of International Oncology, 2023, 50(4): 241-243.

References24

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi:10.3322/caac.21660
[2]	Meijer OC, Koorneef LL, Kroon J. Glucocorticoid receptor modulators[J]. Ann Endocrinol (Paris), 2018, 79(3): 107-111. DOI: 10.1016/j.ando.2018.03.004. doi:S0003-4266(18)30029-5pmid:29731108
[3]	Kalfeist L, Galland L, Ledys F, et al. Impact of glucocorticoid use in oncology in the immunotherapy era[J]. Cells, 2022, 11(5): 770. DOI: 10.3390/cells11050770. doi:10.3390/cells11050770
[4]	Caratti B, Fidan M, Caratti G, et al. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth[J]. Sci Signal, 2022, 15(726): eabm4452. DOI: 10.1126/scisignal.abm4452. doi:10.1126/scisignal.abm4452
[5]	Vesting AJ, Jais A, Klemm P, et al. NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition[J]. Mol Metab, 2022, 66: 101626. DOI: 10.1016/j.molmet.2022.101626. doi:10.1016/j.molmet.2022.101626
[6]	Whirledge S, DeFranco DB. Glucocorticoid signaling in health and disease: insights from tissue-specific GR knockout mice[J]. Endocrinology, 2018, 159(1): 46-64. DOI: 10.1210/en.2017-00728. doi:10.1210/en.2017-00728pmid:29029225
[7]	Matthews LC, Berry AA, Morgan DJ, et al. Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy[J]. Proc Natl Acad Sci U S A, 2015, 112(17): 5479-5484. DOI: 10.1073/pnas.1411356112. doi:10.1073/pnas.1411356112
[8]	Prekovic S, Schuurman K, Mayayo-Peralta I, et al. Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer[J]. Nat Commun, 2021, 12(1): 4360. DOI: 10.1038/s41467-021-24537-3. doi:10.1038/s41467-021-24537-3pmid:34272384
[9]	Jiang Z, Zhang C, Liu X, et al. Dexamethasone inhibits stemness maintenance and enhances chemosensitivity of hepatocellular carcinoma stem cells by inducing deSUMOylation of HIF‑1α and Oct4[J]. Int J Oncol, 2020, 57(3): 780-790. DOI: 10.3892/ijo.2020.5097. doi:10.3892/ijo.2020.5097pmid:32705164
[10]	Escoter-Torres L, Caratti G, Mechtidou A, et al. Fighting the fire: mechanisms of inflammatory gene regulation by the glucocorticoid receptor[J]. Front Immunol, 2019, 10: 1859. DOI: 10.3389/fimmu.2019.01859. doi:10.3389/fimmu.2019.01859pmid:31440248
[11]	Timmermans S, Vandewalle J, Libert C. Dimerization of the glucocorticoid receptor and its importance in (patho)physiology: a primer[J]. Cells, 2022, 11(4): 683. DOI: 10.3390/cells11040683. doi:10.3390/cells11040683
[12]	Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma[J]. Clin Cancer Res, 2019, 25(3): 912-920. DOI: 10.1158/1078-0432.CCR-18-1254. doi:10.1158/1078-0432.CCR-18-1254pmid:30274981
[13]	朱金霞, 刘光伟, 杨培伟. 中医药调控Wnt/β-catenin通路治疗肝细胞癌的研究进展[J]. 中国中医基础医学杂志, 2023, 29(4): 679-686. DOI: 10.19945/j.cnki.issn.1006-3250.2023.04.011. doi:10.19945/j.cnki.issn.1006-3250.2023.04.011
[14]	Liu B, Zhou H, Zhang T, et al. Loss of endothelial glucocorticoid receptor promotes angiogenesis via upregulation of Wnt/β-catenin pathway[J]. Angiogenesis, 2021, 24(3): 631-645. DOI: 10.1007/s10456-021-09773-x. doi:10.1007/s10456-021-09773-xpmid:33650028
[15]	Marchi D, van Eeden FJM. Homeostatic regulation of glucocorticoid receptor activity by hypoxia-inducible factor 1: from physiology to clinic[J]. Cells, 2021, 10(12): 3441. DOI: 10.3390/cells10123441. doi:10.3390/cells10123441
[16]	Tian H, Zhu X, Lv Y, et al. Glucometabolic reprogramming in the hepatocellular carcinoma microenvironment: cause and effect[J]. Cancer Manag Res, 2020, 12: 5957-5974. DOI: 10.2147/CMAR.S258196. doi:10.2147/CMAR.S258196pmid:32765096
[17]	Greulich F, Hemmer MC, Rollins DA, et al. There goes the neighborhood: assembly of transcriptional complexes during the regulation of metabolism and inflammation by the glucocorticoid receptor[J]. Steroids, 2016, 114: 7-15. DOI: 10.1016/j.steroids.2016.05.003. doi:S0039-128X(16)30035-6pmid:27192428
[18]	Ma R, Zhang W, Tang K, et al. Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma[J]. Nat Commun, 2013, 4: 2508. DOI: 10.1038/ncomms3508. doi:10.1038/ncomms3508pmid:24149070
[19]	Cho JH, Lee YM, Starost MF, et al. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ⅰa at the tumor-developing stage[J]. J Inherit Metab Dis, 2019, 42(3): 459-469. DOI: 10.1002/jimd.12056. doi:10.1002/jimd.12056
[20]	Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2020, 39(1): 126. DOI: 10.1186/s13046-020-01629-4. doi:10.1186/s13046-020-01629-4
[21]	Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma[J]. Acta Pharm Sin B, 2022, 12(2): 558-580. DOI: 10.1016/j.apsb.2021.09.019. doi:10.1016/j.apsb.2021.09.019pmid:35256934
[22]	Gnocchi D, Sabbà C, Massimi M, et al. Metabolism as a new avenue for hepatocellular carcinoma therapy[J]. Int J Mol Sci, 2023, 24(4): 3710. DOI: 10.3390/ijms24043710. doi:10.3390/ijms24043710
[23]	Xu L, Xia H, Ni D, et al. High-dose dexamethasone manipulates the tumor microenvironment and internal metabolic pathways in anti-tumor progression[J]. Int J Mol Sci, 2020, 21(5): 1846. DOI: 10.3390/ijms21051846. doi:10.3390/ijms21051846
[24]	Tahmasebi-Birgani M, Ansari H, Carloni V. Defective mitosis-linked DNA damage response and chromosomal instability in liver cancer[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(1): 60-65. DOI: 10.1016/j.bbcan.2019.05.008. doi:10.1016/j.bbcan.2019.05.008

Mechanism of action of glucocorticoid receptors in the growth of hepatoma cells

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References24

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[2]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong.Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells[J]. Journal of International Oncology, 2023, 50(9): 513-519.
[5]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[6]	Ding Hao, Ying Jintao, Fu Maoyong.Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(4): 231-235.
[7]	Zhang Bixia, Ding Jianghua.Immunotherapy for EGFR-mutant non-small cell lung cancer after EGFR-TKI acquired resistance[J]. Journal of International Oncology, 2023, 50(2): 97-101.
[8]	He Ting, Wang Xi, Zhang Huizhong, Liu Xinyang, Wang Huiping, Dong Ke.Diagnostic value of serum TIM-3 in patients with liver cancer[J]. Journal of International Oncology, 2022, 49(9): 537-542.
[9]	Wang Liuxue, Xi Xiaoping, Liu Jingjing, Shen Guomin, Yang Haiping.Research progress of metformin in non-Hodgkin lymphoma[J]. Journal of International Oncology, 2022, 49(7): 436-440.
[10]	Zhang Yumin, Zhao Xianwei, He Qianjin, Chen Jieneng.Value of contrast-enhanced ultrasound combined with serum CXCL8 and CXCR2 in the evaluation of postoperative efficacy of transcatheter arterial chemoembolization for primary liver cancer[J]. Journal of International Oncology, 2022, 49(10): 592-596.
[11]	Di Weihua, Zhao Xuemei.Research progress on the relationship between DNA damage repair genes and liver cancer[J]. Journal of International Oncology, 2022, 49(10): 635-638.
[12]	Du Jiahang, Chen Dong, Chen Yaoting.Research progress of arsenic trioxide in anti-liver cancer mechanism and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2021, 48(9): 572-.
[13]	Han Baojun.Expression of histone acetyltransferase P300 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of International Oncology, 2021, 48(7): 415-419.
[14]	Zhang Yuyuan, Li Zhen, Zhan Pengchao, Li Xin, Ye Shuwen, Wang Caihong, Liu Yang.Progress of biomarkers in liver cancer[J]. Journal of International Oncology, 2021, 48(4): 241-245.
[15]	Li Qianqian, Zhu Xiaodi, Zhao Ronglan, Peng Xiaoxiang.Role of P2X7 receptor in colon cancer progression[J]. Journal of International Oncology, 2021, 48(4): 250-253.